Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease, fibrosis, and cancer. Their lead drug candidate, belapectin (GR-MD-02), is a complex carbohydrate drug that targets galectin-3, a protein implicated in the pathogenesis of fibrotic diseases and cancer. The company is primarily focused on advancing belapectin for the treatment of non-alcoholic steatohepatitis (NASH) with cirrhosis and in combination with immunotherapy for various cancers. Galectin Therapeutics aims to address significant unmet medical needs through its innovative scientific approach.
Serves as the primary corporate office and hub for research and development oversight, clinical trial management, and administrative operations.
The facility comprises office space for administrative, clinical, and regulatory staff, supporting the company's focused drug development programs. Specific architectural highlights for this type of office suite are not publicly emphasized.
As a clinical-stage biotech, the culture is likely focused, results-driven, and collaborative, emphasizing scientific rigor and innovation in a lean operational environment. Employees are typically dedicated to advancing medical science for patient benefit.
The headquarters is central to strategic decision-making, managing pivotal clinical trials for its lead candidate belapectin, and engaging with regulatory bodies, the scientific community, and investors.
Galectin Therapeutics's global presence is primarily manifested through its clinical trial operations. These trials, particularly for its lead candidate belapectin, often involve sites in multiple countries across North America, Europe, and potentially other regions to ensure diverse patient enrollment and gather comprehensive data. While its corporate and R&D management is centralized in the U.S., the company collaborates with international researchers, contract research organizations (CROs), and regulatory agencies as part of its global drug development strategy.
4960 Peachtree Industrial Blvd., Suite 240
Norcross
Georgia
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Galectin Therapeutics' leadership includes:
Galectin Therapeutics has been backed by several prominent investors over the years, including:
In the last 12 months (calculated from mid-2023 to mid-2024), Galectin Therapeutics solidified its financial leadership by appointing Jack W. Callicutt as permanent Chief Financial Officer in December 2023, transitioning him from his prior interim role. No other C-level executive departures or new C-level hires from outside the company have been publicly announced during this specific period.
Discover the tools Galectin Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Galectin Therapeutics primarily uses the email format combining the employee's first initial followed by their last name at the galectintherapeutics.com domain. This is a common pattern for corporate communications.
[first_initial][last]@galectintherapeutics.com
Format
jdoe@galectintherapeutics.com
Example
70%
Success rate
GlobeNewswire • May 7, 2024
Galectin Therapeutics announced it will release its first-quarter 2024 financial results and host a conference call on May 14, 2024, to discuss the results and provide a business update on its programs....more
GlobeNewswire • March 12, 2024
Galectin Therapeutics announced its financial results for the full year 2023 and provided a comprehensive business update, including progress on its NAVIGATE study of belapectin in NASH cirrhosis....more
GlobeNewswire • January 23, 2024
Galectin Therapeutics provided an update on its NAVIGATE Study, detailing advancements in patient screening, site activation for its pivotal trial of belapectin, and reiterated its expectation for an interim analysis in Q4 2024....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Galectin Therapeutics, are just a search away.